Search results

  • Full text

  • Document type

    • Publication year

  • Organisation

Results: 17
Number of items: 17
  • Open Access
    Kouwenhoven, W. M., Robinson, E. J., Hamberg, D., von Oerthel, L., Smidt, M. P., & van der Heide, L. P. (2025). The absence of Pitx3 results in postnatal loss of dopamine neurons and is associated with an increase in the pro-apoptotic Bcl2 factor Noxa and cleaved caspase 3. Cell Death & Disease, 16, Article 230. https://doi.org/10.1038/s41419-025-07552-w
  • Open Access
    Douma, E. H., Smidt, M. P., & van der Heide, L. P. (2024). Boosting endogenous dopamine production: a novel therapeutic approach for Parkinson's disease. Trends in Molecular Medicine, 30(9), 800-803. https://doi.org/10.1016/j.molmed.2024.06.002
  • Open Access
    Douma, E. H., Stoop, J., Lingl, M. V. R., Smidt, M. P., & van der Heide, L. P. (2024). Phosphodiesterase inhibition and Gucy2C activation enhance tyrosine hydroxylase Ser40 phosphorylation and improve 6-hydroxydopamine-induced motor deficits. Cell and Bioscience, 14, Article 132. https://doi.org/10.1186/s13578-024-01312-7
  • Open Access
    Stoop, J., Douma, E. H., van der Vlag, M., Smidt, M. P., & van der Heide, L. P. (2023). Tyrosine hydroxylase phosphorylation is under the control of serine 40. Journal of neurochemistry, 167(3), 376-393. https://doi.org/10.1111/jnc.15963
  • Open Access
    Douma, E. H. (2023). Replenishing dopamine in Parkinson’s disease: Tyrosine hydroxylase Ser40 phosphorylation and phosphodiesterase inhibition. [Thesis, fully internal, Universiteit van Amsterdam].
  • Open Access
    Stoop, J. (2023). Discharging dopamine: Boosting endogenous tyrosine hydroxylase activity as a treatment for Parkinson's disease. [Thesis, externally prepared, Universiteit van Amsterdam].
  • Open Access
    Robinson, E. J. (2021). Mcl1 in control of life and death of dopamine neurons. [Thesis, fully internal, Universiteit van Amsterdam].
  • Open Access
    van de Vis, R. A. J., Moustakas, A., & van der Heide, L. P. (2021). NUAK1 and NUAK2 Fine-Tune TGF-β Signaling. Cancers, 13(13), Article 3377. https://doi.org/10.3390/cancers13133377
  • Open Access
    Robinson, E. J., Aguiar, S., Smidt, M. P., & van der Heide, L. P. (2019). MCL1 as a Therapeutic Target in Parkinson's Disease? Trends in Molecular Medicine, 25(12), 1056-1065. https://doi.org/10.1016/j.molmed.2019.08.009
  • Open Access
    Kolliopoulos, C., Raja, E., Razmara, M., Heldin, P., Heldin, C.-H., Moustakas, A., & van der Heide, L. P. (2019). Transforming growth factor β (TGFβ) induces NUAK kinase expression to fine-tune its signaling output. The Journal of Biological Chemistry, 294(11), 4119-4136. https://doi.org/10.1074/jbc.RA118.004984
Page 1 of 2